Evidence map›Paper›PMID 26027778›Full record

ArticleHuman immunology2015

Development and validation of a sample sparing strategy for HLA typing utilizing next generation sequencing.

Denise M McKinney, Zheng Fu, Lucas Le, Jason A Greenbaum, Bjoern Peters, Alessandro Sette

Abstract read
In one paragraph

Article in Human immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Denise M McKinneyDepartment of Vaccine Development, La Jolla Institute for Allergy and Immunology, 9820 Athena Circle, La Jolla, CA 92037, USA.
Zheng FuBioinformatics Core Facility, La Jolla Institute for Allergy and Immunology, 9820 Athena Circle, La Jolla, CA 92037, USA.
Lucas LeDepartment of Vaccine Development, La Jolla Institute for Allergy and Immunology, 9820 Athena Circle, La Jolla, CA 92037, USA.
Jason A GreenbaumBioinformatics Core Facility, La Jolla Institute for Allergy and Immunology, 9820 Athena Circle, La Jolla, CA 92037, USA.
Bjoern PetersDepartment of Vaccine Development, La Jolla Institute for Allergy and Immunology, 9820 Athena Circle, La Jolla, CA 92037, USA.
Alessandro SetteDepartment of Vaccine Development, La Jolla Institute for Allergy and Immunology, 9820 Athena Circle, La Jolla, CA 92037, USA. Electronic address: alex@liai.org.

Funding

Understanding mechanisms in specific immunotherapy (SIT)U19AI100275 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SETTE, ALESSANDRO · 2012 to 2017
$8.1M
NIAID NIH HHS AI-100275NIAID NIH HHS AI-900044CNIAID NIH HHS AI-900048CNIAID NIH HHS HHSN272201400045CNIAID NIH HHS N01-AI-900042CNIAID NIH HHS U19 AI100275
6 · The paper itself

Abstract

We report the development of a general methodology to genotype HLA class I and class II loci. A Whole Genome Amplification (WGA) step was used as a sample sparing methodology. HLA typing data could be obtained with as few as 300 cells, underlining the usefulness of the methodology for studies for which limited cells are available. The next generation sequencing platform was validated using a panel of cell lines from the International Histocompatibility Working Group (IHWG) for HLA-A, -B, and -C. Concordance with the known, previously determined HLA types was 99%. We next developed a panel of primers to allow HLA typing of alpha and beta chains of the HLA DQ and DP loci and the beta chain of the DRB1 locus. For the beta chain genes, we employed a novel strategy using primers in the intron regions surrounding exon 2, and the introns surrounding exons 3 through 4 (DRB1) or 5 (DQB1 and DPB1). Concordance with previously determined HLA Class II types was also 99%. To increase throughput and decrease cost, we developed strategies combining multiple loci from each donor. Multiplexing of 96 samples per run resulted in increases in throughput of approximately 8-fold. The pipeline developed for this analysis (HLATyphon) is available for download at https://github.com/LJI-Bioinformatics/HLATyphon.

Indexed as

Histocompatibility TestingAllelesCell LineComputational BiologyGene LibraryHigh-Throughput Nucleotide SequencingHLA AntigensHumansLeukocytes, MononuclearPolymerase Chain ReactionReproducibility of ResultsSequence Analysis, DNAWorkflowHLA AntigensHLA typingNext generation sequencingPipelineSample sparing

Identifiers

PMID26027778
PMCPMC4662932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.